21 Jan 2020
Nitrosamines – Risk evaluation
At the end of September EMA began a review under the Article 5(3) of Regulation (EC) No 726/2004 to provide guidance for MAHs on how to avoid nitrosamines in human medicines.
21 Jan 2020
GMP for Medicinal Cannabis – 29th of January
André Luz, the Director of Quality Assurance at Owlpharma, will be presenting a “GMP for Medicinal Cannabis” training on January 29th in collaboration with Formiventos.